TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24362707

Group type: EXPERIMENTAL
Intervention: Vitamin D2 supplementation (vitD2, 3800 IU/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21916687

Group type: EXPERIMENTAL
Intervention: School-based social competence intervention
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Parental training intervention
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1675
Study: 19001508

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg per day
Number of subjects: 4128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4128
Study: 15917194

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g intravenous infusion for 45 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (intravenous infusion)
Number of subjects: 10
Study: 12011684

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy for complications of BRVO
Number of subjects: 0
Study: 10433012

Group type: EXPERIMENTAL
Intervention: Recumbent posture
Number of subjects: 11

Group type: COMPARATOR
Intervention: Upright posture
Number of subjects: 11
Study: 8942013

Group type: EXPERIMENTAL
Intervention: Combination of calcium, vitamin D3, and ascorbic acid supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lactose as a placebo
Number of subjects: 25
Study: 1705725

Group type: COMPARATOR
Intervention: Conventional fractionated radiation (Group I); 1.8 to 2.3 Gy once a day, total dose 30 to 40 Gy, average treatment duration 20 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (Group II); 1.8 to 2 Gy two times a day, total dose 25 to 35 Gy, average treatment duration 10 days
Number of subjects: 55
Study: 6751059

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient entry within 3 hours of onset of infarction
Number of subjects: 0
Study: 30267478

Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg i.v., maximum 8 mg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Label dosing of Diazepam
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 87
Study: 26815798

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Auditory-Tactile-Visual-Vestibular (ATVV) intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Preterm infant care information
Number of subjects: 231
Study: 25899895

Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention (nurse-led, multidisciplinary programme of home/clinic visits)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: NIL-CHF intervention
Number of subjects: 624

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 624
Study: 23221187

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine aqueous solution (PI)
Number of subjects: 12904

Group type: EXPERIMENTAL
Intervention: 2% iodine tincture (IT)
Number of subjects: 12904

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (CHG)
Number of subjects: 12904
Study: 20527505

Group type: EXPERIMENTAL
Intervention: Chewing gum containing sodium tripolyphosphate (1%)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo sugar‐free chewing gum
Number of subjects: 111
Study: 18528292

Group type: EXPERIMENTAL
Intervention: Balloon-occluded retrograde transvenous obliteration (BRTO)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no BRTO)
Number of subjects: 237
Study: 16638499

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 22
Study: 12789036

Group type: EXPERIMENTAL
Intervention: Pressure relief to 0 mm Hg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure relief to 5 mm Hg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure relief to 10 mm Hg
Number of subjects: 12
Study: 10949538

Group type: EXPERIMENTAL
Intervention: Controlled-release (CR) melatonin, average final dose 5.7 mg (2-12 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fast-release (FR) melatonin
Number of subjects: 42
Study: 9012300

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) with varying inspiratory flow rates (pressurization times of < 0.1, 0.5, 1, 1.5, 2 seconds).
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation (PSV) with decreasing inspiratory flow rates.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no or minor nonobstructive lung pathology).
Number of subjects: 12
Study: 8412050

Group type: EXPERIMENTAL
Intervention: Prazosin (PRAZ)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (CTL)
Number of subjects: 6
Study: 2864857

Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy (10 mg three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Metoprolol monotherapy (100 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination therapy (100 mg metoprolol twice daily plus 10 mg nifedipine three times daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study: 30753892

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Meta-analysis of PEAR-2 and PEAR
Number of subjects: 110
Study: 29373333

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Sufentanil (2 mg/ml ropivacaine and 0.25 μg/ml sufentanil)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ropivacaine alone (2 mg/ml ropivacaine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ropivacaine + Sufentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 70
Study: 26778468

Group type: EXPERIMENTAL
Intervention: Same label
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Different labels
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonlinguistic sounds
Number of subjects: 80
Study: 25284993

Group type: EXPERIMENTAL
Intervention: LSS-tele
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: LSS-direct
Number of subjects: 27

Group type: COMPARATOR
Intervention: UCS
Number of subjects: 27
Study: 21752586

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 119

Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 119
Study: 20809058

Group type: EXPERIMENTAL
Intervention: Real rTMS (1000 pulses of subthreshold 10 Hz rTMS for 10 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control rTMS (sham treatment)
Number of subjects: 28
Study: 19034097

Group type: EXPERIMENTAL
Intervention: High-fidelity training model (computerized virtual reality bronchoscopy simulator)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-fidelity training model (nonanatomic model guided by experts)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (low-fidelity and high-fidelity)
Number of subjects: 28
Study: 15929814

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing selective PCI
Number of subjects: 1294

Group type: COMPARATOR
Intervention: Non-diabetic patients undergoing selective PCI
Number of subjects: 1294
Study: 12663288

Group type: EXPERIMENTAL
Intervention: Fortified beverage with 10 micronutrients at physiologic doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonfortified beverage (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fortified beverage
Number of subjects: 0
Study: 10378552

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (after washout)
Number of subjects: 14
Study: 8650875

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of normal saline (15 mL/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg; maximum, 40 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 28
Study: 1632390

Group type: EXPERIMENTAL
Intervention: IS-5-MN (20 mg) at 8 a.m.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: IS-5-MN (20 mg) at 2 p.m.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo at 8 a.m.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo at 2 p.m.
Number of subjects: 18
Study: 4056843

Group type: COMPARATOR
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a low dose of 2 X 10(6) U/m2 intramuscularly daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose of 20 X 10(6) U/m2 intramuscularly daily
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A) at a high dose (20 X 10(6) U/m2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Recombinant DNA-derived interferon alpha (rIFN alpha A)
Number of subjects: 56
Study: 31170224

Group type: EXPERIMENTAL
Intervention: Self-chosen music (10 minutes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Active control (10 minutes of listening to an experimenter-chosen radio documentary)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Age group (younger vs older adults)
Number of subjects: 80
Study: 28795387

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day orally) plus Fuzheng Kang'ai Formula (250 mL, twice per day, orally)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 70
Study: 26891861

Group type: EXPERIMENTAL
Intervention: 8h monitoring interval
Number of subjects: 1346

Group type: COMPARATOR
Intervention: 12h monitoring interval
Number of subjects: 1346
Study: 24686841

Group type: EXPERIMENTAL
Intervention: Low-density nonwords
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-density nonwords
Number of subjects: 61
Study: 20123223

Group type: EXPERIMENTAL
Intervention: Turn-mob program (passive turning and mobilization by a trained relative)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard treatment (turning by nursing staff)
Number of subjects: 223
Study: 16361173

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (PH) 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Atropine 0.02 mg/kg combined with neostigmine 0.03 mg/kg
Number of subjects: 80
Study: 12143227

Group type: EXPERIMENTAL
Intervention: 0.2 mg terlipressin i.v. every 4 hours for 2 days (group I)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1 mg terlipressin i.v. every 4 hours for 5 days (group II)
Number of subjects: 86
Study: 9491067

Group type: EXPERIMENTAL
Intervention: White dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 250 lux)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dim red dawn treatment (1.5 hours from 4:30 a.m. to 6:00 a.m. peaking at 2 lux)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: White dawn treatment
Number of subjects: 12
Study: 7923305

Group type: EXPERIMENTAL
Intervention: Long-acting nicardipine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard nicardipine tablets
Number of subjects: 35

Group type: COMPARATOR
Intervention: Long-acting nifedipine
Number of subjects: 35
Study: 3044874

Group type: EXPERIMENTAL
Intervention: Dipyrone (500 mg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Paracetamol (500 mg)
Number of subjects: 53
Study: 11811084

Group type: COMPARATOR
Intervention: Standard eradication treatment (lansaprasol 30 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid for 14 days)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1000 mg/day plus standard treatment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 1000 mg/day for 14 days
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Standard regimen plus beta carotene (BC) 120 mg/day
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Beta carotene (BC) 120 mg/day for 14 days
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Standard regimen plus allicin 4200 micrograms/day
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Allicin 1200 micrograms/day for 14 days
Number of subjects: 210
Study: 30589387

Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program consisting of ankle stretching and strengthening, balance training, and joint mobilizations, with daily home ankle-strengthening and stretching exercises.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4-week rehabilitation program
Number of subjects: 20
Study: 29708388

Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment plus exercise intervention (ST + EX)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Smoking cessation treatment plus wellness education (ST + CTRL)
Number of subjects: 136
Study: 26944609

Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 25312637

Group type: EXPERIMENTAL
Intervention: Type C lesions
Number of subjects: 3661

Group type: COMPARATOR
Intervention: Bivalirudin monotherapy
Number of subjects: 3661

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3661
Study: 22931760

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Losartan plus Tadalafil
Number of subjects: 124

Group type: COMPARATOR
Intervention: Watch for waiting
Number of subjects: 124
Study: 20143642

Group type: EXPERIMENTAL
Intervention: Consistent ICS use
Number of subjects: 914

Group type: COMPARATOR
Intervention: No ICS use
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Poorly controlled asthma
Number of subjects: 914
Study: 17389305

Group type: EXPERIMENTAL
Intervention: LY451395 0.2 mg BID for 28 days and 1.0 mg BID thereafter (n = 90)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (n = 91)
Number of subjects: 181
Study: 14693973

Group type: EXPERIMENTAL
Intervention: Diabetes case management
Number of subjects: 362

Group type: COMPARATOR
Intervention: Traditional primary care treatment (Control)
Number of subjects: 362
Study: 12154416

Group type: EXPERIMENTAL
Intervention: Insulin infusion (n = 188)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo (saline; n = 193)
Number of subjects: 381
Study: 9840636

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated components fixed without cement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cemented components
Number of subjects: 37

Group type: COMPARATOR
Intervention: Noncoated components fixed without cement
Number of subjects: 37
Study: 8206467

Group type: EXPERIMENTAL
Intervention: 0.25% podophyllotoxin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 0.50% podophyllotoxin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo solution (70% ethanolic vehicle)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Podophyllotoxin (both concentrations)
Number of subjects: 57
Study: 2510257

Group type: EXPERIMENTAL
Intervention: Rioprostil, 600 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 129853

Group type: EXPERIMENTAL
Intervention: Spectinomycin hydrochloride (2.0 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aqueous penicillin combined with probenecid
Number of subjects: 0
Study: 31676651

Group type: EXPERIMENTAL
Intervention: Partial HPSF (structured physical activity sessions only)
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Full HPSF (daily healthy lunch and structured physical activity sessions)
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1676
Study: 28448266

Group type: EXPERIMENTAL
Intervention: Transdermal Continuous Oxygen Therapy (TCOT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Moist Wound Therapy (MWT) with sham device (control)
Number of subjects: 122
Study: 25491768

Group type: EXPERIMENTAL
Intervention: 1-day training, Lumio (magnifying glass with polarized light, 3Gen), Nikon digital camera, and 1 year of feedback on skin lesion pictures sent to the dermatologist.
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1-day training only (control group).
Number of subjects: 78
Study: 24015629

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 23

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 23
Study: 21955757

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined prone and upright position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study: 19628408

Group type: COMPARATOR
Intervention: Green tea consumption (7 or more cups per day)
Number of subjects: 12251

Group type: EXPERIMENTAL
Intervention: Green tea consumption
Number of subjects: 12251
Study: 16863564

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(8) cfu/mL
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(6) cfu/mL
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 at a dose of 1 x 10(10) cfu/mL
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 15223089

Group type: EXPERIMENTAL
Intervention: Accu Drop (AD) plus counseling (C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo drop (PD) plus counseling (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (AD&C and PD&C)
Number of subjects: 60
Study: 11262683

Group type: EXPERIMENTAL
Intervention: Triangular or half-sinusoidal stimuli of 400 ms duration
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Square wave stimuli
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (3 subjects)
Number of subjects: 13
Study: 9048460

Group type: EXPERIMENTAL
Intervention: Bioresorbable barrier (poly[lactic acid])
Number of subjects: 9

Group type: COMPARATOR
Intervention: Expanded polytetrafluoroethylene (e‐PTFE) membranes
Number of subjects: 9
Study: 7748346

Group type: EXPERIMENTAL
Intervention: Korsakoff alcoholics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Korsakoff alcoholics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 3015019

Group type: EXPERIMENTAL
Intervention: Daily acyclovir treatment (200 mg t.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Weekend acyclovir treatment (400 mg t.i.d. on Saturday and Sunday)
Number of subjects: 35
Study: 30286746

Group type: EXPERIMENTAL
Intervention: ART adherence support through peer influence and community engagement
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Addressing poverty and economic independence
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: School attendance and privacy issues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Family support and guardianship issues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Managing multiple medications
Number of subjects: 7
Study: 25830326

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (300,000 to 50 million PFU)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine (3 million PFU or more)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: rVSV-ZEBOV vaccine
Number of subjects: 158
Study: 24246588

Group type: EXPERIMENTAL
Intervention: Family heart‐health intervention (n = 211)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (n = 215)
Number of subjects: 426
Study: 22055281

Group type: EXPERIMENTAL
Intervention: Electronic self-help CBT (n = 216)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil self-help CBT (n = 205)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Waiting-list control (n = 202)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Electronic and paper-and-pencil groups (n = 421 combined)
Number of subjects: 623
Study: 20542468

Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blockers (ARBs)
Number of subjects: 93515

Group type: COMPARATOR
Intervention: Control
Number of subjects: 93515
Study: 18760207

Group type: EXPERIMENTAL
Intervention: Modified mattress locking stitch (MMLS) repair
Number of subjects: 78

Group type: COMPARATOR
Intervention: Simple stitch repair
Number of subjects: 78
Study: 16190390

Group type: EXPERIMENTAL
Intervention: General therapy and UTI after hemorrhage (Group II)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: General therapy (Group I)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (20 patients without hemorrhage)
Number of subjects: 66
Study: 12204667

Group type: EXPERIMENTAL
Intervention: Continue tamoxifen treatment
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Stop tamoxifen treatment
Number of subjects: 306

Group type: COMPARATOR
Intervention: Declined randomisation - Stop tamoxifen
Number of subjects: 306

Group type: COMPARATOR
Intervention: Declined randomisation - Continue tamoxifen
Number of subjects: 306

Group type: COMPARATOR
Intervention: Declined randomisation - Unclear decision
Number of subjects: 306
Study: 10527998

Group type: EXPERIMENTAL
Intervention: HGF concentrations in SGA group (16.9 ± 6.6 ng/ml)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HGF concentrations in AGA group (16.7 ± 9.0 ng/ml)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HGF concentrations in LGA group (20.2 ± 14.8 ng/ml)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Maternal age in AGA group (34.2 ± 5.5 years)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Birth age, birth weight, neonatal height, and placental weight
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IGF-I concentrations
Number of subjects: 104
Study: 7667814

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) concentrates
Number of subjects: 0
Study: 2143637

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7424807

Group type: COMPARATOR
Intervention: High protein diet (45 g protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfur amino acid supplement (15 g protein plus sulfur amino acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (15 g protein)
Number of subjects: 0